Preparation of Antibody-Modified mRNA-LNPs via a Combination of Post-Encapsulation and Post-Insertion
Authors:
Open Access
- 23 July 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (15) , 7157-7166
Abstract
Using ligand-modified lipid nanoparticles (LNPs) to encapsulate messenger RNA (mRNA) has become an important modality for tissue/organ/cell-specific gene delivery. Modifying mRNA-LNPs either with antibodies or their derivatives (Ab-mRNA-LNPs) has emerged as a promising drug delivery system (DDS) due to its efficacy and target specificity. Manufacturing Ab-mRNA-LNPs, however, involves complex and multi-step procedures that include the encapsulation of mRNA followed by the anchoring of antibodies via polyethylene glycol (PEG) linker-conjugated lipids. In this work, we present a seamless strategy for the production of Ab-mRNA-LNPs by integrating the post-encapsulation of mRNA into mRNA-free LNPs (fLNPs) with a post-insertion of ligand-conjugated PEG-lipid (Lig-PEG-lipid). Using a T-cell-targeting model, we further describe how targeting efficacy is influenced by controlling the surface nature of the Ab-mRNA-LNPs either via the modification of PEG-lipids or by replacing the phospholipids. Modification of the DSPE-PEG-methoxy and employment of either DSPC or DPPC significantly improves the accumulation of Ab-mRNA-LNPs in T cells. These findings highlight the importance of LNP surface engineering.Keywords
Funding Information
- Japan Agency for Medical Research and Development (25ae0121051h0002)
- Japan Agency for Medical Research and Development (26ae0121051h0003)
- Japan Agency for Medical Research and Development (JP25bm1123040)
- Tohoku University
- Japan Society for the Promotion of Science (23H00542)
- Japan Society for the Promotion of Science (25K21825)
- NOF CORPORATION
This publication has 26 references indexed in Scilit:
- Balancing Multivalent Avidity and Receptor Availability Governs mRNA Delivery by Antibody-Functionalized Lipid NanoparticlesNano Letters, 2026
- A Post-Encapsulation Method for the Preparation of mRNA-LNPs via the Nucleic Acid-Bridged Fusion of mRNA-Free LNPsNano Letters, 2025
- Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine deliveryJournal of Controlled Release, 2025
- Lipid Nanocarrier‐Based mRNA Therapy: Challenges and Promise for Clinical TransformationSmall, 2024
- The role of lipid components in lipid nanoparticles for vaccines and gene therapyAdvanced Drug Delivery Reviews, 2022
- Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic DeviceNano Letters, 2021
- Self‐Degradable Lipid‐Like Materials Based on “Hydrolysis accelerated by the intra‐Particle Enrichment of Reactant (HyPER)” for Messenger RNA DeliveryAdvanced Functional Materials, 2020
- Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapseAdvanced Drug Delivery Reviews, 2020
- State‐of‐the‐Art Design and Rapid‐Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid DeliverySmall Methods, 2018
- Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structuresBiochimica et Biophysica Acta (BBA) - Biomembranes, 2001